clinical trial · NCT05275400
A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin
Eli Lilly and Company·phase3·completed·n = 986
Type 2 DiabetesInsulin Efsitora AlfaInsulin Degludec
brief summary
The reason for this study is to see if the study drug insulin efsitora alfa (LY3209590) is safe and effective in participants with Type 2 diabetes that have already been treated with basal insulin. The study consists of a 3-week screening/lead-in period, a 78-week treatment period and a 5-week safety follow-up period. The study will last up to 86 weeks.
started
Mar 8, 2022
primary completion
May 15, 2024
completion
May 15, 2024
last updated
Jun 3, 2025
official title
A Phase 3, Multicenter, Randomized, Parallel-Design, Open-Label Trial to Evaluate the Efficacy and Safety of LY3209590 Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin (QWINT-3)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol